Drug Profile
NXN 188
Alternative Names: NXN-188Latest Information Update: 08 Jun 2015
Price :
$50
*
At a glance
- Originator NeurAxon
- Class Small molecules
- Mechanism of Action Calcitonin gene-related peptide antagonists; Nitric oxide synthase inhibitors; Serotonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Migraine
Most Recent Events
- 08 Jun 2015 Phase-II development of an oral formulation of NXN 188 is ongoing in the US, Canada and Denmark
- 01 Jan 2015 NXN 188 licensed to Knight Therapeutics in Canada, Israel, South Africa and Russia
- 31 Aug 2012 Preclinical study pharmacodynamics data in Migraine presented at the 14th World Congress on Pain (WCP-2012)